Your session is about to expire
← Back to Search
Rho-Kinase Inhibitor
AR-12286 for Glaucoma
Phase 2
Waitlist Available
Research Sponsored by New York Glaucoma Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
IOP above the target range or visual field progression with use of maximum standard drug therapy
Patients with open-angle glaucoma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Study Summary
This trial will evaluate the ability of AR-12286 to lower eye pressure in patients with glaucoma who are at risk of needing surgery. If successful, the drug could help patients delay or avoid surgery.
Who is the study for?
This trial is for open-angle glaucoma patients with high eye pressure despite using all standard medications, who are looking to avoid surgery. Participants must be able to attend treatment for 6 months and give written consent. Those with other types of glaucoma, recent use of certain eye meds, significant health issues like uncontrolled diabetes or previous eye surgery can't join.Check my eligibility
What is being tested?
The study tests if AR-12286 ophthalmic solutions (0.5% and 0.7%) can lower eye pressure in glaucoma patients over a period of six months and potentially delay or prevent the need for surgical intervention.See study design
What are the potential side effects?
Possible side effects may include mild discomfort in the eyes, redness, allergic reactions to ingredients in the solution such as benzalkonium chloride, or temporary visual disturbances.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My eye pressure is too high or my vision is getting worse despite using the strongest medications.
Select...
I have been diagnosed with open-angle glaucoma.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
IOP Reduction
Secondary outcome measures
Tolerance and Lasting IOP Effect
Trial Design
2Treatment groups
Experimental Treatment
Group I: 0.7% Rho-Kinase InhibitorExperimental Treatment1 Intervention
AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
Group II: 0.5% Rho-Kinase InhibitorExperimental Treatment1 Intervention
AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
Find a Location
Who is running the clinical trial?
New York Glaucoma Research InstituteLead Sponsor
2 Previous Clinical Trials
20 Total Patients Enrolled
2 Trials studying Glaucoma
20 Patients Enrolled for Glaucoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with angle-closure glaucoma.I cannot perform reliable vision tests.I understand what this study is about.I have had surgery for glaucoma before.I haven't used any eye medication in the last 30 days, except for glaucoma treatment or dry eye drops.I am willing to attend all scheduled follow-up visits.I do not have any major health issues like uncontrolled diabetes or heart problems that could affect the study.My eye pressure is too high or my vision is getting worse despite using the strongest medications.I have been diagnosed with open-angle glaucoma.
Research Study Groups:
This trial has the following groups:- Group 1: 0.5% Rho-Kinase Inhibitor
- Group 2: 0.7% Rho-Kinase Inhibitor
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What has been the general consensus on the safety of Rho-Kinase Inhibitor (AR-12286)?
"Rho-Kinase Inhibitor (AR-12286) is still in Phase 2 clinical trials. While there is some data supporting safety, none of the evidence collected thus far suggests that the medication is effective."
Answered by AI
Is it possible to join this clinical trial currently?
"No, this research is no longer recruiting patients according to the latest information on clinicaltrials.gov. The original posting date was June 1st, 2014 and the last update was April 23rd, 2015; however, there are 205 other trials with open recruitment at this time."
Answered by AI
Who else is applying?
What site did they apply to?
Glaucoma Associates of New York
What portion of applicants met pre-screening criteria?
Met criteria
Why did patients apply to this trial?
My eyesight is getting worse and the eye drop medication doesn't seem to be helping as much as it use to.
PatientReceived 1 prior treatment
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger